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Exportin-1 (XPO1) is a nuclear export protein with >220
cargo proteins, including tumor suppressors and cell
cycle modulators. Selinexor is a SINE (Selective Inhibitor
of Nuclear Export) compound that has been administered
to >900 cancer patients in Phase I and II trials to date,
with evidence of efficacy and tolerability. Selinexor blocks
nuclear export of NFAT1c, STAT1 and STAT3, which
are implicated in regulating the inhibitory T cell receptor
PD-1 and its ligand, PD-L1. We hypothesized that seli-
nexor would upregulate T cell checkpoint molecule
expression, and that combination treatment with anti-
PD-1 or anti-PD-L1 would thereby enhance the ability of
selinexor to elicit antitumor activity.
Selinexor increased PD-1 gene expression by ~2-fold
in normal lymphocytes and induced PD-L1 gene expres-
sion in tumor cell lines. Mice bearing syngeneic colon
tumors (colon26) treated with selinexor and anti-PD-1
for 2 weeks demonstrated a significant reduction in
tumor growth rate (P < 0.05), while monotherapy with
either agent had no significant effect on tumor growth.
Similar results were obtained in mice bearing syngeneic
B16F10 melanoma tumors, whereby combined treatment
with selinexor + anti-PD-1 was superior to either single
agent alone (p < 0.034). Combined therapy of mice
bearing B16F10 tumors with selinexor and anti-PD-L1
was similarly effective, with significantly smaller tumors
at the study endpoint (p < 0.001). No weight loss or
signs of toxicity were evident in any in vivo study.
Immunophenotypic analysis by flow cytometry
revealed that selinexor alone or in combination with
anti-PD-1/anti-PD-L1 significantly increased the percen-
tage of splenic NK cells (p≤0.050), while selinexor ±
anti-PD-L1 significantly increased the percentage of
splenic Th1 T cells (p≤0.011), all compared to vehicle
treated mice. Interestingly, combining selinexor with
anti-PD-L1 significantly decreased the percentage of
splenocytes that expressed PD-L1 (p < 0.001). These
data indicate that the efficacy of selinexor may be
enhanced by disrupting the pre-existing PD-1/PD-L1
signaling in effector cells (T and NK cells).
Altogether, these data suggest that the efficacy of seli-
nexor in combination with anti-PD-1 or anti PD L1 in
mouse syngeneic tumor models may be due to both dis-
rupting immunosuppressive PD-1/PD-L1 signaling and
increasing the frequency of potentially tumor reactive
NK cells and Th1 T cells. This provides a rational basis
for this treatment combination as a novel therapeutic
approach for advanced cancer.
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